Webinar Home Page
Personalized Therapies and Best Clinical Practices for Lung Cancer 2017
January 6, 2016 – January 6, 2017
Click below to view
Dr. Spigel Dr. Garon
Webinar #4229a
DEBATE 1: Checkpoint inhibition for refractory NSCLC, with or without testing for PD-L1
Dr. Spigel
Dr. Garon
Dr. Spigel
Webinar #4229b
Combination Immune-therapy for refractory NSCLC
Dr. Spigel
Dr. Goldman
Webinar #4229c
Expert Panel Discussion and Q&A
Faculty
Dr. Neal Dr. West
Webinar #4229d
DEBATE #2: Plasma–based Next Generation Sequencing (NGS) liquid biopsy testing is sufficiently reliable and cost-effective to be used routinely in advanced NSCLC to identify actionable mutations.
Dr. Neal
Dr. West
Dr. Garon
Webinar #4229e
Genetic profiles in younger NSCLC patients: Should younger patients receive Next Generation Sequencing (NGS) Testing any differently than older adults?
Dr. Garon
Dr. Goldman
Webinar #4229f
Implications of NGS testing on therapy selection
Dr. Goldman
Faculty
Webinar #4229g
Expert Panel Discussion and Q&A
Faculty
J. Koeller
Webinar #4229h
Value-Based Care: What does a cancer Health Care Professional (HCP) Need to Know? What is meant by value-based cancer care? What are the current strategies that are being used to establish this versus fee for service?
J. Koeller
Dr. Evans
Webinar #4229i
How Appropriate Therapeutic and Supportive Care Helps Appropriate Patient Care in the Value Proposition: Defining the benefits
Dr. Evans
Dr. Goldman
Webinar #4229j
Expert Panel Discussion and Q&A
Faculty
Jim M. Koeller, MS
Webinar #4229k
Pharmacists: An In-Depth Role of Cancer Therapy Value.
Jim Koeller
Marianne Davies, OCN
Webinar #4229l
Nurses: The Rise of the Patient in Cancer Therapy Value and Therapy Selection: How can the oncology nurse enhance this?
Marianne Davies, OCN
Dr. Gralla
Webinar #4229m
The increasingly critical role of supportive care in the improvement in NSCLC patient outcomes and therapy value: And the increasing role of patient reported outcomes as clinical endpoints.
Dr. Gralla
Dr. Goldman
Webinar #4229n
Expert Panel Discussion and Q&A
Faculty
Dr. Bunn Dr. Wakelee
Webinar #4229o
DEBATE #3: What should be the standard of care today with FDA-approved agents for Initial therapy for advanced/metastatic squamous NSCLC patients?
Dr. Bunn
Dr. Wakelee
Dr. Neal
Webinar #4229p
What are the clinical applications for chemotherapy for squamous NSCLC patients? Is there a role for combinations with immune therapy? For combinations with targeted therapy? Is there a role for continuation maintenance chemotherapy?
Dr. Neal
Dr. Natale
Webinar #4229q
What are the clinical applications of anti-EGFR targeted and anti-VEGFR & therapies for squamous NSCLC? How do they compare with the other FDA approved options?
Dr. Natale
Dr. Hirsch
Webinar #4229r
What is the role of immune therapy for squamous NSCLC?How does immune therapy compare with other FDA approved options in the 2nd line setting?
Dr. Hirsch
Faculty
Webinar #4229s
Expert Panel Discussion, Q&A
Faculty
Dr. Garon Dr. Bunn
Webinar #4229t
DEBATE #4: A patient has progressed on crizotinib, and then was placed on second-line alectinib, and again subsequently progressed. What next?
Dr. Garon
Dr. Bunn
Dr. Bunn
Webinar #4229u
What is the new therapeutic paradigm for using the current and emerging generations of ALK-directed therapies for NSCLC? What factors have impacted sequencing of anti-ALK agents?
Dr. Bunn
Faculty
Webinar #4229v
Expert Panel Discussion, Q&A
Faculty
Dr. Neal Dr. Wakelee
Webinar #4229w
DEBATE #5: When a NSCLC patient relapses on initial therapy with an EGFR-directed therapy, and tests negative for T790M Mutation, what should be the subsequent therapy?
Dr. Neal
Dr. Wakelee
Dr. West
Webinar #4229x
What is the new therapeutic paradigm for using the three generations of FDA-approved EGFR-directed therapies for NSCLC? What is the impact of new clinical trials data, the T790M Mutation and other EGFR mutation data on therapeutic selection and sequencing?
Dr. West
Faculty
Webinar #4229y
Expert Panel Discussion, Q&A
Faculty